Bausch+Lomb Results Presentation Deck

Top 10 Revenues (Includes FX Impact) Rank Product/Franchises 1 Surgical Consumables¹ 2 Ocuvite® + PreserVisionⓇ 3 4 7 8 9 10 Ⓡ SofLens Biotrue ONEday Bausch+Lomb ULTRA® Surgical Implantables¹ Surgical Equipment¹ renu® LumifyⓇ Biotrue® Solutions Franchise BAUSCH + LOMB 1Q23 $95M $81M $60M $52M $51M $44M $44M $42M $38M $35M FY22 $359M $387M $246M $201M $177M $188M $171 M $176M $131 M $153M 4Q22 $94M $114M $62M $50M $43M $49M $45M $47M $35M $37M 3Q22 $85M $98M $62M $53M $46M $45M $42M $44M $30M $39M 2Q22 $93M $94M $61M $49M $44M $49M $42M $43M $35M $39M 1. As of the first quarter of 2023, certain products were recategorized across the consumables, impantables and equipment product categories. This change was made as management believes this better aligns these products in their respective categories. Prior period presentations of product categories have been conformed to current product category structure to allow investors to evaluate results between periods on a consistent basis. 1Q22 $87M $81M $61M $49M $44M $45M $42M $42M $31M $38M 22

View entire presentation